Other
Chronic HBV Infection
0
Pipeline Programs↗
1
Active Trials↗
6
Companies Involved↗
Chronic HBV Infection is an early-stage landscape with 0 programs across 6 companies. The most active players are Arbutus Biopharma Corporation, Suzhou HepaThera Biotech Co., Ltd., GSK.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
15
clinical trials
Completed5 · 33%
Unknown status5 · 33%
Terminated2 · 13%
Withdrawn2 · 13%
Active, not recruiting1 · 7%
Clinical Trials
Trial Activity
15 trials
Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection
Active, not recruiting·
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT06706310·116 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT06706310·116 enrolledOptimization of Antiviral Therapy of Chronic HBV Infection
Completed·—·N/A·NCT01623778·67 enrolled
Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention
Unknown status·—·N/A·NCT04030039·420 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)